BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies.
BioMS Medical will receive an upfront payment of $87 million, as
The proposed mechanism of action, according to BioMS Medical, is to reintroduce "a state of 'tolerance' to a critical portion of the nerve's myelin basic protein that is an immunological site of attack in many MS patients.
Woollard has been Lead Independent Director for BioMS Medical Corporation since 2005.
Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp.
Kevin Giese, President and CEO of BioMS Medical, discussing this release will be available at www.
This once again positions BioMS with a unique opportunity that addresses a significant unmet medical need and has blockbuster potential," said Kevin Giese, President and CEO of BioMS Medical.
The clinical investigators, study site personnel and BioMS Medical's drug development team all have done an outstanding job of recruiting patients and conducting this trial at the highest quality standards," said Dr.
Spectral represents the type of development opportunity that BioMS is seeking and ideally suited for: investment in a late-stage clinical program with a large market opportunity, and the ability to assist in the successful development of a project using our management expertise," said Kevin Giese, President and CEO of BioMS Medical.
EDMONTON, Alberta, January 19 /PRNewswire/ -- BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), announced today that it has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS.
Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of all products covered by the license agreement.
EDMONTON, Canada, December 10 /PRNewswire/ -- BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received a Notice of Acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its pivotal Phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS).
OTC Bulletin Board: AIMM) today announced its licensee, BioMS Medical Corp.
INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company and BioMS Medical Corp.
EDMONTON, July 17 /PRNewswire-FirstCall/ -- BioMS Medical Corp.